EA201101583A1 - Ингибиторы pi3 киназы или mtor - Google Patents

Ингибиторы pi3 киназы или mtor

Info

Publication number
EA201101583A1
EA201101583A1 EA201101583A EA201101583A EA201101583A1 EA 201101583 A1 EA201101583 A1 EA 201101583A1 EA 201101583 A EA201101583 A EA 201101583A EA 201101583 A EA201101583 A EA 201101583A EA 201101583 A1 EA201101583 A1 EA 201101583A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
mtor inhibitors
compounds
present
variables
Prior art date
Application number
EA201101583A
Other languages
English (en)
Other versions
EA019700B1 (ru
Inventor
Кристин Эндрюс
Юньсинь И. Бо
Шон Букер
Виктор Дж. Си
Ноэль Д'Энжело
Брэдли Дж. Херберич
Фан-Цао Хон
Клер Л.М. Джексон
Брайан А. Лэнмэн
Хонъю Ляо
Лонбинь Лю
Нобуко Нишимуа
Марк Х. Нормэн
Липин Х. Петтас
Энтони Б. Рид
Эдриан Л. Смит
Сейфу Тадесс
Нуриа А. Тамайо
Бинь Ву
Райан Вурц
Кевин Ян
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201101583A1 publication Critical patent/EA201101583A1/ru
Publication of EA019700B1 publication Critical patent/EA019700B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы I или их фармацевтически приемлемым солямспособам лечения заболеваний или состояний, таких как рак, при помощи соединений настоящего изобретения; и фармацевтическим композициям, содержащим соединения настоящего изобретения, где переменные параметры указаны в данном документе.
EA201101583A 2009-04-28 2010-04-27 Ингибиторы pi3 киназы или mtor EA019700B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17352009P 2009-04-28 2009-04-28
US25853209P 2009-11-05 2009-11-05
PCT/US2010/032593 WO2010126895A1 (en) 2009-04-28 2010-04-27 Inhibitors of pi3 kinase and / or mtor

Publications (2)

Publication Number Publication Date
EA201101583A1 true EA201101583A1 (ru) 2012-05-30
EA019700B1 EA019700B1 (ru) 2014-05-30

Family

ID=42315845

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101583A EA019700B1 (ru) 2009-04-28 2010-04-27 Ингибиторы pi3 киназы или mtor

Country Status (24)

Country Link
US (2) US8362241B2 (ru)
EP (1) EP2424859B1 (ru)
JP (1) JP5697662B2 (ru)
KR (1) KR20120007540A (ru)
CN (1) CN102548984B (ru)
AR (1) AR076486A1 (ru)
AU (1) AU2010241723B2 (ru)
BR (1) BRPI1015262A2 (ru)
CA (1) CA2758986C (ru)
CL (1) CL2011002691A1 (ru)
CO (1) CO6440596A2 (ru)
CR (1) CR20110634A (ru)
EA (1) EA019700B1 (ru)
HK (1) HK1167862A1 (ru)
IL (1) IL215731A0 (ru)
MA (1) MA34207B1 (ru)
MX (1) MX2011011335A (ru)
NZ (1) NZ595572A (ru)
PE (1) PE20121159A1 (ru)
SG (1) SG175364A1 (ru)
TW (1) TW201103902A (ru)
UY (1) UY32582A (ru)
WO (1) WO2010126895A1 (ru)
ZA (1) ZA201108101B (ru)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
MX2011009796A (es) 2009-03-20 2011-12-14 Amgen Inc Inhibidores de la cinasa pi3.
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
FR2958290B1 (fr) 2010-03-30 2012-10-19 Sanofi Aventis Procede de preparation de derives de sulfonamido-benzofurane
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
HUP1000330A2 (en) 2010-06-18 2011-12-28 Sanofi Sa Process for the preparation of dronedarone and the novel intermediates
RU2550038C2 (ru) * 2010-12-02 2015-05-10 Медпакто Инк. Новое производное пуринилпиридиниламино-2,4-дифторфенилсульфонамида, его фармацевтически приемлемая соль, способ его получения и фармацевтическая композиция, обладающая ингибирующей активностью в отношении raf-киназы, содержащая данное соединение в качестве активного ингредиента
EP2675816A4 (en) * 2011-02-14 2014-08-13 Univ Alberta BORONIC ACID CATALYSTS AND METHODS OF USE FOR THE ACTIVATION AND TRANSFORMATION OF CARBOXYLIC ACIDS
AU2012225382B2 (en) * 2011-03-09 2016-10-27 Celgene Avilomics Research, Inc. PI3 kinase inhibitors and uses thereof
HUP1100165A2 (en) 2011-03-29 2012-12-28 Sanofi Sa Process for preparation of dronedarone by n-butylation
HUP1100167A2 (en) 2011-03-29 2012-11-28 Sanofi Sa Process for preparation of dronedarone by mesylation
SG10201604682VA (en) * 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
US9376425B2 (en) 2011-09-27 2016-06-28 Amgen, Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
CN103102349B (zh) * 2011-11-14 2017-03-15 北京赛林泰医药技术有限公司 蛋白激酶抑制剂及其组合物和用途
US9550781B2 (en) 2011-11-14 2017-01-24 Centaurus Biopharma Co., Ltd. Kinase modulating compounds, compositions containing the same and use thereof
FR2983198B1 (fr) 2011-11-29 2013-11-15 Sanofi Sa Procede de preparation de derives de 5-amino-benzoyl-benzofurane
EP2617718A1 (en) 2012-01-20 2013-07-24 Sanofi Process for preparation of dronedarone by the use of dibutylaminopropanol reagent
US9221778B2 (en) 2012-02-13 2015-12-29 Sanofi Process for preparation of dronedarone by removal of hydroxyl group
WO2013121234A1 (en) * 2012-02-14 2013-08-22 Sanofi Process for the preparation of dronedarone by oxidation of a sulphenyl group
WO2013124745A1 (en) 2012-02-22 2013-08-29 Sanofi Process for preparation of dronedarone by oxidation of a hydroxyl group
WO2013178337A1 (en) 2012-05-31 2013-12-05 Sanofi Process for preparation of dronedarone by grignard reaction
EP2882726A4 (en) * 2012-08-09 2016-04-06 Neuropore Therapies Inc ARYL AND HETEROARYL-SUBSTITUTED BENZENE DERIVATIVES AS MODULATORS OF PI-3 KINASE SIGNALING PATHWAYS
FR2994572B1 (fr) * 2012-08-17 2015-04-17 Centre Nat Rech Scient Pyrido[3,2-d]pyrimidines trisubstituees, leurs procedes de preparation et leurs utilisation en therapeutique
WO2014130470A1 (en) 2013-02-19 2014-08-28 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
MX2015012427A (es) 2013-03-14 2016-01-12 Amgen Inc Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
WO2015013581A1 (en) 2013-07-26 2015-01-29 Update Pharma Inc. Combinatorial methods to improve the therapeutic benefit of bisantrene
CN104513235B (zh) * 2013-09-02 2017-12-05 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
ES2687593T3 (es) * 2013-09-25 2018-10-26 Vertex Pharmaceuticals Inc. Un inhibidor selectivo de fosfatidilinositol 3-quinasa-gamma
BR112016010564A2 (pt) 2013-11-11 2017-10-10 Amgen Inc terapia de combinação incluindo um inibidor de mdm2 e um ou mais agentes farmaceuticamente ativos para tratamento de cânceres
CN104744446B (zh) * 2013-12-30 2019-06-25 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
MA40240B1 (fr) 2014-06-19 2019-03-29 Ariad Pharma Inc Composés hétéroaryle d'inhibition de la kinase
EP3351533A4 (en) * 2015-09-18 2019-03-06 Kaken Pharmaceutical Co., Ltd. BIARY DERIVATIVE AND MEDICAMENT THEREOF
JP6768838B2 (ja) * 2016-02-03 2020-10-14 サムジン ファーマシューティカル カンパニー，リミテッド Ｒａｆキナーゼおよび血管内皮成長因子受容体を阻害するピリジン誘導体、この製造方法、これを含む薬剤学的組成物およびこの用途
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
ES2930198T3 (es) * 2016-10-14 2022-12-07 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
WO2018089499A1 (en) * 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
JP6469272B2 (ja) * 2017-03-01 2019-02-13 科研製薬株式会社 ビアリール誘導体又はその塩からなる医薬
EA201992166A1 (ru) 2017-03-14 2020-02-04 Басф Се Гербицидные азины
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CA3075046A1 (en) 2017-09-08 2019-03-14 Amgen Inc. Inhibitors of kras g12c and methods of using the same
CN111372579B (zh) 2017-10-30 2023-08-22 神经孔疗法股份有限公司 取代的苯基磺酰基苯基三唑硫酮和其用途
UA128288C2 (uk) 2018-03-08 2024-05-29 Інсайт Корпорейшн СПОЛУКИ АМІНОПІРАЗИНДІОЛУ ЯК ІНГІБІТОРИ PI3K-<font face="Symbol">g</font>
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
CA3099737A1 (en) 2018-05-14 2019-11-21 Ariad Pharmaceuticals, Inc. Pharmaceutical salts of pyrimidine derivatives and method of treating disorders
WO2020050890A2 (en) 2018-06-12 2020-03-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP7292394B2 (ja) * 2018-12-21 2023-06-16 サルティゴ・ゲーエムベーハー ２－アルコキシ－４－アミノ－５－メチル－ピリジン及び／又は２－アルコキシ－４－アルキルアミノ－５－メチル－ピリジンを調製するためのプロセス
WO2020146779A1 (en) * 2019-01-11 2020-07-16 The Regents Of The University Of California mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (es) 2019-05-21 2022-01-04 Amgen Inc Formas en estado solido.
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
WO2021259315A1 (zh) * 2020-06-23 2021-12-30 深圳福沃药业有限公司 化合物的盐以及包含盐的药物组合物
CN116283467B (zh) * 2023-01-18 2024-06-11 四川大学 一种合成二芳基烷基甲烷的方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6526896A (en) 1995-07-22 1997-02-18 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
US20030232789A1 (en) 1999-12-15 2003-12-18 Allen Darin Arthur Salicylamides as serine protease and factor xa inhibitors
AU2001250850A1 (en) 2000-03-17 2001-10-03 Dupont Pharmaceuticals Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
US20040082627A1 (en) 2002-06-21 2004-04-29 Darrow James W. Certain aromatic monocycles as kinase modulators
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
WO2004099127A1 (en) 2003-05-07 2004-11-18 Novo Nordisk A/S Novel compounds as kinase inhibitors
US7781591B2 (en) 2006-06-13 2010-08-24 Wyeth Llc Substituted 3-cyanopyridines as protein kinase inhibitors
KR20070026390A (ko) 2004-01-23 2007-03-08 암젠 인코포레이션 화합물 및 사용방법
AU2005245386B2 (en) * 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
JP5089377B2 (ja) 2005-03-11 2012-12-05 全薬工業株式会社 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
EP2049497A2 (en) 2005-05-19 2009-04-22 Astex Therapeutics Limited Pyrimidine derivatives as hsp90 inhibitors
WO2007011721A1 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0520657D0 (en) * 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2637658C (en) 2006-01-23 2012-07-17 Amgen Inc. Aurora kinase modulators and method of use
AU2007212345A1 (en) * 2006-02-06 2007-08-16 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2035436B1 (en) * 2006-06-26 2011-05-25 UCB Pharma S.A. Fused thiazole derivatives as kinase inhibitors
US20090233926A1 (en) 2006-09-14 2009-09-17 Astrazeneca 2-benzimidazolyl-6-morpholino-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
US20090270390A1 (en) 2006-09-14 2009-10-29 Astrazeneca Pyrimidine derivatives
WO2008032077A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives
CN101563339A (zh) 2006-09-14 2009-10-21 阿斯利康(瑞典)有限公司 作为 p i 3 k和 m t o r抑制剂用于治疗增殖性疾病的 2 -苯并咪唑基 - 6 -吗啉代 - 4 - (氮杂环丁烷、吡咯烷、哌啶或氮杂)嘧啶衍生物
US20090325954A1 (en) 2006-09-14 2009-12-31 Sam Butterworth 2-benzimidazolyl-6-morpholino-4-phenylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032060A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders
WO2008032041A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
WO2008032033A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032036A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032089A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
WO2008032091A1 (en) 2006-09-14 2008-03-20 Astrazeneca Ab 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders
AU2008213808B2 (en) 2007-02-06 2011-11-10 Novartis Ag PI 3-kinase inhibitors and methods of their use
US8138183B2 (en) 2007-07-09 2012-03-20 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mTOR kinase and/or PI3K
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−９４５
KR20100042643A (ko) 2007-07-09 2010-04-26 아스트라제네카 아베 증식성 질환을 치료하기 위한 삼중치환된 피리미딘 유도체
PE20090880A1 (es) 2007-07-26 2009-08-06 Novartis Ag Compuestos heterociclicos como inhibidores de fosfatidilinositol 3-cinasa
US20100311736A1 (en) 2007-10-22 2010-12-09 Glaxosmithkline Llc Pyridosulfonamide derivatives as p13 kinase inhibitors
WO2009093981A1 (en) 2008-01-23 2009-07-30 S Bio Pte Ltd Triazine compounds as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
WO2009120094A2 (en) 2008-03-27 2009-10-01 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
MY155653A (en) 2008-05-23 2015-11-13 Wyeth Llc Triazine compounds as p13 kinase and mtor inhibitors
AR073354A1 (es) 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
TW201022208A (en) 2008-10-30 2010-06-16 Herbalscience Group Llc Tryptase enzyme inhibiting aminopyridines
US8598209B2 (en) 2008-10-31 2013-12-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
MX2011006333A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
US8937078B2 (en) 2009-02-10 2015-01-20 Janssen Pharmaceutica Nv Quinazolinones as prolyl hydroxylase inhibitors
MX2011008674A (es) 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
US8785628B2 (en) 2009-03-06 2014-07-22 Ucb Pharma, S.A. Triazine derivatives as kinase inhibitors
CA2756067A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
EP2440051A4 (en) 2009-06-08 2012-12-19 California Capital Equity Llc TRIAZINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

Also Published As

Publication number Publication date
KR20120007540A (ko) 2012-01-20
UY32582A (es) 2010-11-30
EA019700B1 (ru) 2014-05-30
ZA201108101B (en) 2012-07-25
US20100273764A1 (en) 2010-10-28
CA2758986A1 (en) 2010-11-04
CO6440596A2 (es) 2012-05-15
NZ595572A (en) 2013-07-26
CN102548984B (zh) 2015-11-25
EP2424859A1 (en) 2012-03-07
MA34207B1 (fr) 2013-05-02
WO2010126895A1 (en) 2010-11-04
AU2010241723A1 (en) 2011-11-17
JP5697662B2 (ja) 2015-04-08
SG175364A1 (en) 2011-11-28
IL215731A0 (en) 2012-01-31
JP2012525395A (ja) 2012-10-22
US20130079303A1 (en) 2013-03-28
HK1167862A1 (en) 2012-12-14
US8772480B2 (en) 2014-07-08
EP2424859B1 (en) 2015-04-08
CR20110634A (es) 2012-01-06
PE20121159A1 (es) 2012-09-19
BRPI1015262A2 (pt) 2016-05-03
AU2010241723B2 (en) 2012-12-13
CA2758986C (en) 2014-05-27
MX2011011335A (es) 2011-11-18
CL2011002691A1 (es) 2012-03-16
AR076486A1 (es) 2011-06-15
CN102548984A (zh) 2012-07-04
US8362241B2 (en) 2013-01-29
TW201103902A (en) 2011-02-01

Similar Documents

Publication Publication Date Title
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
EA201390085A1 (ru) Композиции ингибиторов киназ для лечения рака
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
IN2014KN00929A (ru)
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201200373A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
EA201391485A1 (ru) Способы и композиции для лечения нейродегенеративных заболеваний
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
EA201101533A1 (ru) Гетероциклические соединения в качестве ингибиторов mek
EA201171415A1 (ru) Ингибиторы белков семейства iap
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU